All comments are in my opinion. Do your own due diligence prior to purchasing any stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Finally!
Started researching in the summer, found they are one of very few players in the Psilocybin game.
Got lucky with my Nov call.
GLTY
$LITT
Good call.
Record volume today and nice movement.
$LITT
BMSND
2000-1 reverse split
Go in 3 months ago - one of the few players.
Looks ready to go.
$LITT
That's promising - just need an update.
Come on Yu!
$ETNI
Current Report Filing (8-k)
Date : 07/02/2019 @ 11:57AM
Source : Edgar (US Regulatory)
Stock : Regen Biopharma, Inc. (QB) (RGBPP)
Quote : 0.0125 0.0 (0.00%) @ 8:04AM
Current Report Filing (8-k)
Tweet Print
Alert
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 27, 2019
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
Commission File No. 333-191725
4700 Spring Street, St 304, La Mesa, California 91942
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 3.02 Unregistered Sales of Equity Securities
On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). On June 27, 2019 Zander converted $340,000 of the principal amount of the Note into 194,285, 714 shares of the Series A Preferred stock of Regen as per the terms and conditions of the Note.
Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos and Caven also serve as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of NR2F6 intellectual property licensed to Zander by KCL Therapeutics, Inc. for veterinary applications. KCL Therapeutics Inc. is a majority owned subsidiary of Regen.
The foregoing description of the abovementioned Note is not complete and is qualified in its entirety by reference to the text of the Note , which was filed with the Securities and Exchange Commission as Exhibit 10.1 of Regen’s Form 8-K filed on October 4, 2018 and incorporated in this Item 8.01 by reference.
Item 9.01 Exhibits .
Exhibit No. Description of Exhibit
10.1 $350,000 Convertible Promissory Note *
* Incorporated by Reference to Exhibit 10.1 of Regen’s Form 8-K filed on October 4, 2018
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: July 2, 2019 By: /s/ David Koos
David Koos
Chief Executive Officer
I want to sell mine back to Koosie for $100K.
Looks like it's starting again...
you first.
bye bye
GLTY
Happy I held my shares here.
Hopefully good news to follow shortly.
$ETNI
So nice to see others taking pleasure in people losing money.
They're just doing their job ;)
$RGBP
You can see the desperation...
$RGBP
Loading more - getting close here.
$RGBP
NEWS
https://www.prnewswire.com/news-releases/regen-biopharma-inc-determines-its-lead-nr2f6-agonist-ready-for-inflammatory-bowel-disease-animal-studies-893176445.html
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
These upcoming studies are going to be conducted as a joint venture between Regen BioPharma, Inc. and Zander Therapeutics Inc.
NEWS PROVIDED BY
Regen BioPharma, Inc.
16:00 ET
SHARE THIS ARTICLE
SAN DIEGO, October 4, 2018 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). The Company will pursue this testing as a joint venture with Zander Therapeutics Inc. Zander Therapeutics, Inc. has been granted an exclusive license by Regen to develop and commercialize Regen's NR2F6 intellectual property for veterinary applications.
IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA.
"Our ex-vivo studies with RG-NAH005 support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "We have elected to look at IBD first as the cytokine profile which is suppressed by RG-NAH005 ex-vivo seems to be potentially important in treating IBD."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.
"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "As IBD is both an important issue in both humans and animals, the joint venture of these studies is appropriate for Regen as well as Zander in their pursuit of small molecule therapies for treating autoimmune diseases."
David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Harry Lander serves as President and Chief Scientific Officer of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Lander and Caven also serve as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
NEWS $RGBP
https://www.prnewswire.com/news-releases/regen-biopharma-inc-determines-its-lead-nr2f6-agonist-ready-for-inflammatory-bowel-disease-animal-studies-893176445.html
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
These upcoming studies are going to be conducted as a joint venture between Regen BioPharma, Inc. and Zander Therapeutics Inc.
NEWS PROVIDED BY
Regen BioPharma, Inc.
16:00 ET
SHARE THIS ARTICLE
SAN DIEGO, October 4, 2018 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). The Company will pursue this testing as a joint venture with Zander Therapeutics Inc. Zander Therapeutics, Inc. has been granted an exclusive license by Regen to develop and commercialize Regen's NR2F6 intellectual property for veterinary applications.
IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA.
"Our ex-vivo studies with RG-NAH005 support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "We have elected to look at IBD first as the cytokine profile which is suppressed by RG-NAH005 ex-vivo seems to be potentially important in treating IBD."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.
"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "As IBD is both an important issue in both humans and animals, the joint venture of these studies is appropriate for Regen as well as Zander in their pursuit of small molecule therapies for treating autoimmune diseases."
David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Harry Lander serves as President and Chief Scientific Officer of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Lander and Caven also serve as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
Yup, Koos' shell game... but all that won't matter as long as there is a cure under one of them $$$$.
$RGBP
Traz, could you please sticky today's news.
Thanks.
$RGBP
$RGBP - Record Volume.
Beautiful!
$RGBP
Bash clan in full force.
We are getting close folks!
$RGBP
$ETNI - some action today.
RGBP Patent Application News
https://markets.businessinsider.com/news/stocks/regen-biopharma-inc-files-new-composition-of-matter-patent-application-based-on-its-successful-modulation-of-nr2f6-by-its-small-molecule-compounds-1027515539
Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds
PRESS RELEASE PR Newswire
Sep. 6, 2018, 04:00 PM
Related Stocks
Regen BioPharma
0.01
0.00 (-1.71%)
9/6/2018
Regen BioPharma Inc
Disclaimer
Get real-time Regen BioPharma charts here >>
SAN DIEGO, September 6, 2018 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").
As previously noted by the Company, NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Based upon the Company's screening programs for treating autoimmune diseases such as Lupus, the data gathered provided support for the filing of this patent application.
Additionally, the Company is moving forward with its NR2F6 antagonist small molecule program designed to unleash the cancer-killing potential of a patient's own immune system.
"The patent application lists molecules that activate NR2F6. As we continue to develop our small molecule program, we learn more about the molecular structures key to activating NR2F6 and develop more optimized compounds," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "Thus, we continue to file for patent protection for these unique molecules."
David Koos, Ph.D., CEO of Regen BioPharma, Inc., added, "We continue to ensure the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at https://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
https://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
RGBP Patent Application News
https://markets.businessinsider.com/news/stocks/regen-biopharma-inc-files-new-composition-of-matter-patent-application-based-on-its-successful-modulation-of-nr2f6-by-its-small-molecule-compounds-1027515539
Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds
PRESS RELEASE PR Newswire
Sep. 6, 2018, 04:00 PM
Related Stocks
Regen BioPharma
0.01
0.00 (-1.71%)
9/6/2018
Regen BioPharma Inc
Disclaimer
Get real-time Regen BioPharma charts here >>
SAN DIEGO, September 6, 2018 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").
As previously noted by the Company, NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Based upon the Company's screening programs for treating autoimmune diseases such as Lupus, the data gathered provided support for the filing of this patent application.
Additionally, the Company is moving forward with its NR2F6 antagonist small molecule program designed to unleash the cancer-killing potential of a patient's own immune system.
"The patent application lists molecules that activate NR2F6. As we continue to develop our small molecule program, we learn more about the molecular structures key to activating NR2F6 and develop more optimized compounds," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "Thus, we continue to file for patent protection for these unique molecules."
David Koos, Ph.D., CEO of Regen BioPharma, Inc., added, "We continue to ensure the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at https://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
https://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
Who would have thunk that you'd still be here and I'd be adding until you're gone?
oh wait, I DID!
Loading all week!
$RGBP
Absolutely, but not for the slander here.
I guess that will be for the courts to decide.
I'll take deletion or indictment.
GLTY
$RGBP
$ETNI 8-K Out
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2018
Commission File Number 333-154989
ENTEST GROUP INC.
(Exact Name of Company as Specified in Charter)
Nevada 26-3431263
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)
4700 Spring Street, Suite 304, La Mesa California 91942
(Address of principal executive offices) (Zip Code)
619-702-1404
(Company’s telephone number, including area code)
ENTEST BIOMEDICAL, INC.
(Former name, address and fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 1.01 Entry into a Material Agreement
On July 3, 2018 Zander Therapeutics, Inc. (“Zander”) purchased 3,500,000 of the Series A preferred Shares of Regen Biopharma, Inc. (“Shares”) owned by Entest Group, Inc. from Entest Group, Inc. (“Owner”) for the price of $35,000 USD cash.
David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest. Zander is a 58.14% owned subsidiary of Entest as of May 31, 2018.
David R. Koos, who serves as Chairman and Chief Executive Officer of Regen Biopharma, Inc. also serves as Chairman and Chief Executive Officer of Entest. Regen Biopharma, Inc. is under common control with Entest
On July 3, 2018 Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018.
David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest. Zander is a 58.14% owned subsidiary of Entest as of May 31, 2018.
On July 5, 2018 Zander entered into a collaboration and development agreement (“Agreement”) with Ampersand Biopharmaceuticals, Inc. (“Ampersand”) whereby the parties agreed to cooperate in a research and development program to establish the use of NR2F6 agonists and antagonists coupled with Ampersand’s proprietary transdermal drug delivery system (“Amperzans”) in the treatment of various disorders such as arthritis, atopic dermatitis and cancer in companion animals such as dogs and cats.
Ownership of inventions arising during and in the course of the Parties’ performance under the Agreement, and related intellectual property rights, shall be jointly owned by both parties with the following exceptions :
Ampersand shall solely own all Inventions relating to the Ampersand Technology (technology claims related Ampersand’s transdermal penetration and delivery and any Improvements made thereto during the term of the agreement) and/or to methods of using or manufacturing the Ampersand Technology, whether made by employees, independent contractors or agents of either Party or jointly by employees, independent contractors or agents of both Parties (“Ampersand Inventions”). Such Inventions and patents and patent applications claiming such Inventions are included in this agreement with the same rights and privileges as Background Rights.
Zander shall solely own all Inventions relating to the Zander Technology (technology claims related to the NR2F6 Agonist or Antagonist) .and/or to methods of using or manufacturing the Zander Technology, whether made by employees, independent contractors or agents of either Party or jointly by employees, independent contractors or agents of both Parties (“Zander Inventions”). Such Inventions and patents and patent applications claiming such Inventions are included in this agreement with the same rights and privileges as Background Rights.
The agreement is contingent upon each party successfully funding its part of the research and development work to be performed by Ampersand and Zander pursuant to the Agreement (“ Workplan”) , estimated by the parties to be approximately $1,330,000 per party. Should sufficient funds fail to be raised by both Parties the Agreement and associated Workplan are null and void. The Agreement does not impose any responsibility on any party to complete said funding.
2
The Term of the Agreement shall commence on the Effective Date and will continue unless terminated due to material breach by either party , financial insolvency of either party or the mutual written consent of the Parties. Upon thirty (30) days' written notice, either Party shall be entitled to terminate its financial and developmental obligations under this Agreement for convenience, including, but not limited to either Party having no further business interest in the Development Program.
Any successful monetization of Developed Technology will result in the equal sharing (i.e. 50% to Ampersand and 50% to Zander) of any consideration related to such Developed Technology including, but not limited to, equity, up-front, royalty, milestone and other payments or in-kind consideration associated with any sale, license or sublicense agreement. Such equal sharing of any consideration will be net of any expenses incurred. Should the Developed Technology be developed, marketed, commercialized and/or sold by either Party, the expenses and revenues of such activity will be shared equally. Developed Technology is defined in the Agreement as any and all ideas, inventions, work of authorship, work product, materials, technologies, discoveries, improvements, know-how, techniques, and other deliverables, whether patentable or unpatentable, copyrightable or uncopyrightable, including, but not limited to, any documentation, formula, design, device, code, improvement, method, process, discovery, concept, development, machine or contribution, that a Party conceives, makes, reduces to practice or develops, in whole or in part, alone or in conjunction with others, during or as a result of conducting the development program contemplated by this Agreement.
Neither party shall be entitled to practice, commercialize, market, develop, or otherwise derive a benefit from, financial or otherwise ("Exploit"), or grant third parties, including Affiliates, any rights under the Developed Technology or Development Rights in the Field to make, have made, use, have used, sell, have sold, offer to sell or import, Commercialize, or otherwise Exploit Developed Products in the Field, or grant any third party, including Affiliates, any rights to do any of the above, without the prior written consent of the other Party.
A Developed Product is defined in the Agreement as any product for use in the Field that is developed during the Term of this Agreement (i) the making, manufacture, use, sale or importation of which is covered by any Development Rights, and/or (ii) which includes or incorporates any Developed Technology. “Development Rights” are defined in the Agreement as any and all patent, copyright, trademark, trade secret and other intellectual property rights in and to the Developed Technology, whether now known or hereafter recognized in any jurisdiction. Field as defined in the Agreement means the use of Amperzans for the treatment of any malady in dogs or cats
The foregoing description of the abovementioned Agreement between Zander and Ampersand is not complete and is qualified in its entirety by reference to the text of the abovementioned agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.3 and incorporated in this Item 1.01 by reference.
David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest. Zander is a 58.14% owned subsidiary of Entest as of May 31, 2018.
3
Item 8.01 Other Events
On July 5, 2018 and July 3, 2018 respectively David Koos and Harry Lander assigned to Zander their entire right , title and interest throughout the world in the inventions, improvements and all patent applications that are subject of an application for patent protection filed with the United States Patent and Trademark Office on June 14, 2018 entitled “Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals” The abovementioned application regards methods of using small molecule compounds as immune modulators; as well as compounds, solid forms and compositions thereof that are immune modulators and that exhibit desirable characteristics thereof; as well as to methods of making the compounds, solid forms and composition thereof. Harry Lander currently serves as President and Chief Scientific Officer of Zander and also serves on the Board of Directors of Zander.
David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest. Zander is a 58.14% owned subsidiary of Entest as of May 31, 2018.
Item 9.01 Exhibits .
Exhibit No. Description of Exhibit
10.1 STOCK PURCHASE AGREEMENT
10.2 SUBLEASE
10.3 AMPERSAND AGREEMENT
4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENTEST GROUP, INC.
Dated: July 5, 2018 By: /s/ David Koos
David Koos
Chief Executive Officer
Happy I loaded more today!
Couldn't resist upon seeing the increased efforts on this board.
Have a great weekend - next week could be fun.
$RGBP
do some basic research.
GLTY
$RGBP
100%, because they get paid to do so.
GLTY
$RGBP
Excellent.
Received my shares today as well.
ZANDER THERAPEUTICS INC COMMON STOCK
Y007197
0.0000
Still don't have mine yet... Scotia iTrade is always slow though.
GLTY
$ETNI
Beautiful.
Thanks.
$ETNI
Has anyone received their Zander shares yet?
$ETNI
Record Date (May 30th) fast approaching if you want dividend shares.
$ETNI
Record Date for Dividend announced - people getting in before the pop.
Scooped-up all the cheap shares.
$ETNI
volume!
$ETNI
Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.
https://www.prnewswire.com/news-releases/entest-group-inc-declares-property-dividend-of-3000000-common-shares-of-zander-therapeutics-inc-682283482.html
News provided by
Entest Group, Inc. ?
10:13 ET
Share this article
?
?
?
?
?
?
?
SAN DIEGO, May 10, 2018 /PRNewswire/ --
On May 10, 2018, Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to:
(a) Holders of record of the outstanding common shares of ETNI as of the record date, which is May 30, 2018.
(b) Holders of record of the shares of any outstanding series of the preferred shares of ETNI as of the record date, which is May 30, 2018.
Shareholders of ETNI shall receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of ETNI held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of ETNI will occur on June 11, 2018 ("Distribution Date"). No fractional shares will be distributed. Where the distribution to the shareholder would result in a fractional share, that distribution will be rounded down to the nearest whole share amount.
About Zander Therapeutics Inc. and Entest Group Inc.:
Zander Therapeutics is a subsidiary of Entest Group Inc. (OTCPINK: ETNI), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as an "orphan nuclear receptor," which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information:
Zander Therapeutics, Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
info@zandertherapeutics.com
http://www.zandertherapeutics.com
SOURCE Entest Group, Inc.